The multicentre EU-PRIORITY led by the Steno Diabetes Center in Copenhagen investigated use of the CKD273 urinary proteomic biomarker to predict development of microalbuminuria in patients with Type 2 diabetes and early preventative intervention with spironolactone in high-risk individuals. Dr Gemma Currie and Professor Christian Delles as representatives of the University of Glasgow have been involved in the project from its inception and successfully recruited over 300 participants to the trial locally, ranking Glasgow among the top 3 recruiting centre,
After 7 years of hard work we are pleased to report that the trial has now completed and the proteomic results were presented by Dr Currie at a dedicated symposium at the 55th EASD annual meeting in Barcelona in September. In total 1775 participants were recruited across Europe and followed for up to 4 years.
We reported that CKD273 did accurately predict onset of microalbuminuria and development of CKD3 independent of traditional risk parameters including blood pressure, HbA1c, eGFR and urine albumin: creatinine ratio at baseline. Although CKD273 won’t be arriving at the diabetes outpatient clinic just yet this is an important step forward in clinical evaluation of urinary proteomics
First published: 31 October 2019